ES2535404T3 - Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama - Google Patents

Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama

Info

Publication number
ES2535404T3
ES2535404T3 ES09764134.4T ES09764134T ES2535404T3 ES 2535404 T3 ES2535404 T3 ES 2535404T3 ES 09764134 T ES09764134 T ES 09764134T ES 2535404 T3 ES2535404 T3 ES 2535404T3
Authority
ES
Spain
Prior art keywords
chemotherapy
breast cancer
cyclophosphamide
subject
vegf antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09764134.4T
Other languages
English (en)
Other versions
ES2535404T5 (es
Inventor
Gwendolyn Fyfe
See Chun Phan
Xian Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42154236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2535404(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2535404T3 publication Critical patent/ES2535404T3/es
Publication of ES2535404T5 publication Critical patent/ES2535404T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un anticuerpo anti-VEGF para uso en un procedimiento de tratamiento de cáncer de mama localmente recurrente o metastásico en un sujeto, comprendiendo el procedimiento administrar al sujeto un régimen de tratamiento que comprende una cantidad eficaz de al menos un producto quimioterapéutico y un anticuerpo anti-VEGF, en el que dicho sujeto no ha recibido ninguna quimioterapia por cáncer de mama localmente recurrente o metastásico, y/o no ha recibido quimioterapia complementaria anterior por recurrencia en 12 meses o menos desde la última dosis; y en el que la quimioterapia del régimen de tratamiento comprende la administración de FEC: 5-fluorouracilo, epirubicina y ciclofosfamida o FAC: 5-fluorouracilo, doxorubicina y ciclofosfamida o AC: doxorubicina y ciclofosfamida o EC: epirubicina y ciclofosfamida; y en el que el régimen de tratamiento alarga eficazmente la supervivencia libre de progresión del sujeto.

Description

imagen1

Claims (1)

  1. imagen1
ES09764134.4T 2008-11-22 2009-11-20 Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama Active ES2535404T5 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11710208P 2008-11-22 2008-11-22
US117102P 2008-11-22
US17800909P 2009-05-13 2009-05-13
US178009P 2009-05-13
US17930709P 2009-05-18 2009-05-18
US179307P 2009-05-18
PCT/US2009/065381 WO2010059969A2 (en) 2008-11-22 2009-11-20 Anti-angiogenesis therapy for the treatment of breast cancer

Publications (2)

Publication Number Publication Date
ES2535404T3 true ES2535404T3 (es) 2015-05-11
ES2535404T5 ES2535404T5 (es) 2018-11-19

Family

ID=42154236

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13189711.8T Active ES2611337T3 (es) 2008-11-22 2009-11-20 Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama
ES09764134.4T Active ES2535404T5 (es) 2008-11-22 2009-11-20 Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13189711.8T Active ES2611337T3 (es) 2008-11-22 2009-11-20 Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama

Country Status (28)

Country Link
US (5) US20100143351A1 (es)
EP (3) EP2361085B9 (es)
JP (4) JP6041489B2 (es)
KR (3) KR20180117734A (es)
CN (2) CN105214086B (es)
AR (1) AR074203A1 (es)
AU (1) AU2009316409A1 (es)
BR (1) BRPI0916138A2 (es)
CA (1) CA2744158A1 (es)
CL (1) CL2011001186A1 (es)
CY (1) CY1118549T1 (es)
DK (2) DK2361085T4 (es)
ES (2) ES2611337T3 (es)
HR (1) HRP20170059T1 (es)
HU (2) HUE024872T2 (es)
IL (2) IL212998A (es)
LT (1) LT2752189T (es)
MX (2) MX2011005383A (es)
PH (1) PH12014502507A1 (es)
PL (2) PL2752189T3 (es)
PT (1) PT2752189T (es)
RU (1) RU2531948C2 (es)
SG (1) SG171780A1 (es)
SI (2) SI2361085T2 (es)
SM (1) SMT201700173T1 (es)
TW (2) TWI612971B (es)
WO (1) WO2010059969A2 (es)
ZA (1) ZA201103321B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
KR20180117734A (ko) * 2008-11-22 2018-10-29 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
SG10201401123VA (en) 2010-02-23 2014-08-28 Genentech Inc Anti-Angiogenesis Therapy For The Treatment Of Ovarian Cancer
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
PL2825558T3 (pl) 2012-03-13 2019-11-29 Hoffmann La Roche Terapia skojarzona w leczeniu raka jajnika
DK3626270T3 (da) 2013-08-26 2024-01-15 Novartis Ag Behandling af kardiovaskulære sygdomme
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
EP3164154A1 (en) * 2014-07-03 2017-05-10 Imclone, LLC Combination therapy
AU2015289798B2 (en) 2014-07-14 2019-09-12 University Of Utah Research Foundation In situ solidifying complex coacervates and methods of making and using thereof
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
SG10202007237UA (en) * 2016-02-04 2020-09-29 Immune System Key Ltd Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2019084548A1 (en) * 2017-10-27 2019-05-02 University Of Utah Research Foundation COMPLEX LIQUID IN SITU SOLIDIFICATION COASTALITIES FOR LOCAL ADMINISTRATION OF ANTI-ANGIOGENIC AGENTS OR CHEMOTHERAPEUTIC AGENTS
JP7410876B2 (ja) 2018-01-26 2024-01-10 フルイデックス メディカル テクノロジー，リミティッド ライアビリティ カンパニー 血管閉塞のためにその場凝固複合コアセルベートを使用する装置及び方法
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN112262157A (zh) * 2018-03-09 2021-01-22 加利福尼亚大学董事会 化药抗性癌症的组合治疗
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111710425A (zh) * 2020-06-19 2020-09-25 复旦大学附属中山医院 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
PE20252164A1 (es) * 2023-01-19 2025-09-04 Jiangsu Hengrui Pharmaceuticals Co Ltd Conjugado de anticuerpo-farmaco anti-her2 para el tratamiento del cancer de mama

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CN101014365B (zh) 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20080248033A1 (en) * 2006-12-19 2008-10-09 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
EP2125016A2 (en) * 2007-02-01 2009-12-02 Genetech, Inc. Combination therapy with angiogenesis inhibitors
KR20180117734A (ko) 2008-11-22 2018-10-29 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US11379945B2 (en) 2019-02-27 2022-07-05 Google Llc Grayscale histogram generation

Also Published As

Publication number Publication date
PL2361085T5 (pl) 2018-12-31
TW201023887A (en) 2010-07-01
WO2010059969A3 (en) 2010-08-05
SG171780A1 (en) 2011-07-28
IL212998A0 (en) 2011-07-31
MX340724B (es) 2016-07-22
CN105214086B (zh) 2019-09-27
EP2361085B2 (en) 2018-07-18
TW201609140A (zh) 2016-03-16
KR20110086863A (ko) 2011-08-01
US20210093715A1 (en) 2021-04-01
DK2361085T4 (en) 2018-10-08
CN105214086A (zh) 2016-01-06
RU2531948C2 (ru) 2014-10-27
SMT201700173T1 (it) 2017-05-08
DK2752189T3 (en) 2017-01-16
ES2535404T5 (es) 2018-11-19
JP2017031160A (ja) 2017-02-09
PL2752189T3 (pl) 2017-04-28
EP2361085B9 (en) 2019-01-02
WO2010059969A8 (en) 2011-02-03
US20170100478A1 (en) 2017-04-13
CN102223897A (zh) 2011-10-19
SI2752189T1 (sl) 2017-02-28
RU2011125518A (ru) 2012-12-27
MX2011005383A (es) 2011-06-06
EP3178478A1 (en) 2017-06-14
US20150246124A1 (en) 2015-09-03
SI2361085T2 (sl) 2018-11-30
JP2018138583A (ja) 2018-09-06
CA2744158A1 (en) 2010-05-27
BRPI0916138A2 (pt) 2015-11-17
CL2011001186A1 (es) 2012-02-24
US20100143351A1 (en) 2010-06-10
KR20180117734A (ko) 2018-10-29
EP2361085B1 (en) 2015-02-25
HUE032693T2 (en) 2017-10-30
CN102223897B (zh) 2015-09-23
TWI542359B (zh) 2016-07-21
HRP20170059T1 (hr) 2017-03-10
ES2611337T3 (es) 2017-05-08
EP2752189B1 (en) 2016-10-26
PT2752189T (pt) 2017-02-02
EP2361085A2 (en) 2011-08-31
SI2361085T1 (sl) 2015-06-30
IL212998A (en) 2016-02-29
KR101807319B1 (ko) 2017-12-11
IL243741A0 (en) 2016-04-21
KR20170015525A (ko) 2017-02-08
JP2012509889A (ja) 2012-04-26
DK2361085T3 (en) 2015-03-09
HUE024872T2 (en) 2016-02-29
AR074203A1 (es) 2010-12-29
US20160243227A1 (en) 2016-08-25
PH12014502507A1 (en) 2016-01-18
PL2361085T3 (pl) 2015-08-31
TWI612971B (zh) 2018-02-01
ZA201103321B (en) 2012-08-29
HK1213177A1 (zh) 2016-06-30
AU2009316409A1 (en) 2010-05-27
CY1118549T1 (el) 2017-07-12
EP2752189A1 (en) 2014-07-09
WO2010059969A2 (en) 2010-05-27
JP2020128389A (ja) 2020-08-27
LT2752189T (lt) 2017-02-10
JP6850562B2 (ja) 2021-03-31
JP6041489B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
MX342894B (es) Dosis de inmunoconjugados de anticuerpos y sn-38 para eficacia mejorada y toxicidad reducida.
MX2017012991A (es) Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito.
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
DOP2012000291A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer de mama
CL2009000721A1 (es) Combinacion que comprende un anticuerpo aislado anti-igf1r o un fragmento de fijacion de antigeno del mismo en asociacion con leucovorina y 5-fluorouracilo, leucovorina o sunitinib opcionalmente asociado con otro agente quimioterapeutico; y su uso para el tratamiento o prevencion del cancer colorectal.
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
PA8635501A1 (es) Uso de un anticuerpo para el tratamiento del lupus
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
AR054254A1 (es) Terapia adyuvante con trastuzumab (herceptin registrado)
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
AR071728A1 (es) Terapia con intervalos para el tratamiento del tinnitus
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
AR075982A1 (es) Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
AR065319A1 (es) Prevencion y tratamiento de pcvd subclinica
AR112015A1 (es) Composiciones sólidas para administración oral
AR096184A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpos para cd22-fármaco
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
MX2022001133A (es) Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).